LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open, an ATP 250 tournament, and a partnership with San Diego native and tennis pro Brandon Nakashima. The sponsorships further represent DermTech’s commitment to the San Diego community and goal of raising awareness on the importance of sun safety and skin checks to aid in the early detection of melanoma.
The San Diego Open, held at the Barnes Tennis Center from September 27 through October 3, 2021, features a 28-player singles draw and a 16-team doubles draw. As event sponsor, DermTech is aiming to help educate attendees and the San Diego community on the value of practicing sun safety and the importance of regular skin checks at the signature outdoor event.
“As a company deeply rooted in the San Diego community, DermTech is honored to sponsor the San Diego Open and kick-off a great partnership with Brandon Nakashima,” said John Dobak, M.D., CEO of DermTech. “We are looking forward to participating in this fantastic tennis event and bringing recognition to the importance of sun safety and skin health, in general.”
As a DermTech ambassador and tennis pro that spends a great deal of his time outdoors, Nakashima will shed a spotlight on sun safety, bring attention to the crucial need for skin checks and the DermTech Melanoma Test, the first non-invasive test that enables dermatologists to check an atypical mole painlessly and noninvasively for melanoma.
“My parents are front-line healthcare workers who have always stressed the importance of taking care of my health, particularly my skin,” said Brandon Nakashima. “As professional tennis players, we spend a lot of time outside in the sun, and I am glad I can help bring awareness to DermTech, its DermTech Melanoma Test and the need for sun safety.”
For more information about DermTech, please visit: www.dermtech.com.
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: (1) expected timing and benefits of the Company’s renovation and occupancy of the newly leased property, and (2) the performance, patient benefits, cost‑effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.